**Abstract**

**Background:** The long-term target of drug therapy for schizophrenia is prevention of recurrence/relapse and rehabilitation into society, for which maintenance of favorable medication adherence is important. We have been investigating the influence of treatment with a base compound of blonanserin (BNS) or risperidone (RIS) on the objective/subjective evaluations of patients.

**Methods:** Schizophrenic patients treated with RIS as a base compound at the psychiatric outpatient clinic of Kurume University Hospital were allocated to a group with a switch to BNS and RIS dose adjustment, and followed for 24 weeks (randomized open study). The evaluation items were the Drug Attitude Inventory-10 (DAI-10), Life Assessment Scale for the Mentally Ill (LASMI), sexual function, efficacy based on PANSS, and safety based on body weight and prolactin level. Fifteen patients in the BNS group (32.1 ± 6.7 years old) and 15 patients in the RIS group (33.7 ± 7.5 years old) followed for 24 weeks were included in analysis. To evaluate cognitive function, change of oxy-Hb concentration was observed using multi-channel NIRS. Changes in oxy-Hb value were measured at bilateral recording points (22 on each side) while performing a Japanese word chain game (shiritori).

**Results:** DAI-10 was significantly improved in the BNS group after 20 and 24 weeks compared with that in the RIS group. No significant difference was observed in PANSS. Body weight variation was significantly smaller in the BNS than RIS group at 20 and 24 weeks. The prolactin level was significantly lower in the BNS than RIS group. The oxy-Hb value significantly increased in the frontal pole region only in the BNS group.

**Discussion:** The feeling toward taking BNS was better than that of RIS, and the incidence of sexual dysfunction was low, suggesting that the medication adherence to BNS is easy to maintain and improves cognitive function.
